GoodWe Technologies Co., Ltd. (SHA:688390)

Verve Therapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,112	1,073	1,838	1,577	1,231	1,088
Trading Asset Securities	5.38	14.89	0.24	80.15	70.45	271.99
Cash & Short-Term Investments	1,117	1,088	1,839	1,657	1,302	1,360
Cash Growth	23.17%	-40.81%	10.98%	27.28%	-4.31%	296.92%
Accounts Receivable	1,562	1,089	830.26	736.53	671.94	427.46
Other Receivables	140.5	129.62	92.54	97.04	32.01	24.08
Receivables	1,702	1,219	922.81	833.57	703.95	451.55
Inventory	2,183	2,638	1,944	1,579	854.97	349.56
Prepaid Expenses	-	-	-	10.97	-	-
Other Current Assets	306.45	323.96	313.4	169.64	79.32	25.91
Total Current Assets	5,309	5,269	5,019	4,250	2,940	2,187
Property, Plant & Equipment	1,857	2,020	1,560	1,090	533.98	281.81
Long-Term Investments	266.64	263.43	273.28	208.15	88.91	26.44
Goodwill	33.97	33.97	9.19	9.19	17.92	-
Other Intangible Assets	111.03	111.62	113.78	73.2	76.01	30.61
Long-Term Deferred Tax Assets	212.25	202.83	46.27	59.91	22.16	12
Long-Term Deferred Charges	39.28	45.49	63.63	61.14	9.89	4.07
Other Long-Term Assets	5.54	5.19	26.01	47.17	25.87	17.31
Total Assets	7,834	7,952	7,111	5,799	3,715	2,560
Accounts Payable	2,023	1,459	2,137	2,312	1,644	898.5
Accrued Expenses	95.78	169.4	163.72	119.44	111.18	64.84
Short-Term Debt	1,357	1,323	260.14	50.05	-	-
Current Portion of Long-Term Debt	21.65	25.04	5.48	-	-	-
Current Portion of Leases	-	39.18	19.09	26.17	7.48	-
Current Income Taxes Payable	86.94	49.75	81.27	83.07	9.08	13.13
Current Unearned Revenue	441.31	345.5	229.32	321.26	103.89	84.16
Other Current Liabilities	638.07	1,049	803.84	378.43	108.78	15.27
Total Current Liabilities	4,664	4,461	3,700	3,290	1,984	1,076
Long-Term Debt	-	168.54	71.27	-	-	-
Long-Term Leases	141.36	252.08	144.15	139.05	13.39	-
Long-Term Unearned Revenue	40.3	33.7	28.67	3.89	1.07	1.69
Long-Term Deferred Tax Liabilities	10.03	8.91	0.12	0	4.97	0
Other Long-Term Liabilities	104.11	114.51	106.58	84.7	33.14	25.41
Total Liabilities	4,959	5,039	4,051	3,518	2,037	1,103
Common Stock	242.59	242.59	172.89	123.2	88	88
Additional Paid-In Capital	925.28	919.43	1,012	993.76	971.98	946.87
Retained Earnings	1,569	1,597	1,788	1,133	589.53	415.6
Treasury Stock	-10	-10	-	-	-	-
Comprehensive Income & Other	2.74	1.03	9.58	7.31	6.41	6.22
Total Common Equity	2,729	2,750	2,983	2,257	1,656	1,457
Minority Interest	145.47	163.59	77.3	23.63	21.86	-0.03
Shareholders' Equity	2,875	2,913	3,060	2,281	1,678	1,457
Total Liabilities & Equity	7,834	7,952	7,111	5,799	3,715	2,560
Total Debt	1,520	1,808	500.13	215.28	20.87	-
Net Cash (Debt)	-402.73	-719.9	1,339	1,442	1,281	1,360
Net Cash Growth	-	-	-7.14%	12.54%	-5.85%	351.98%
Net Cash Per Share	-1.71	-3.03	5.50	5.93	5.31	6.93
Filing Date Shares Outstanding	233.57	242.48	241.94	241.47	241.47	241.47
Total Common Shares Outstanding	233.57	242.48	241.94	241.47	241.47	241.47
Working Capital	644.99	808.23	1,318	959.66	955.61	1,112
Book Value Per Share	11.69	11.34	12.33	9.35	6.86	6.03
Tangible Book Value	2,584	2,604	2,860	2,175	1,562	1,426
Tangible Book Value Per Share	11.06	10.74	11.82	9.01	6.47	5.91
Buildings	-	1,245	501.82	479.12	230.1	196.51
Machinery	-	1,034	754.12	544.35	246.06	122.83
Construction In Progress	-	32.02	485.18	153.48	110.76	6.5

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.